Shares of Divi’s Laboratories jumped 5% following a 64% YoY surge in Q2 FY27 net profit to Rs 1,127 crore. Brokerage Jefferies raised its target price by 23% to Rs 12,550, citing robust CDMO business expansion, strong EBITDA margins, and a solid GLP peptide pipeline.